In the phase II/III GATSBY trial, T-DM1 was not superior to conventional chemotherapy with taxane in previously treated HER2-positive advanced gastric cancer (OS: 7.9 vs. 8.6 months) (s. This evidence concerns the gene ERBB2 and gastric cancer.